A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

Recruiting

Phase 1

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

Sponsor:

Fusion Pharmaceuticals Inc.

Code:

NCT06147037

Conditions

Advanced Solid Tumor

Metastatic Colorectal Carcinoma

Head and Neck Squamous Cell Carcinoma

Non-small Cell Lung Cancer

Pancreatic Ductal Adenocarcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

FPI-2053

[111In]-FPI-2107

[225Ac]-FPI-2068

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-15. This information was provided to ClinicalTrials.gov by Fusion Pharmaceuticals Inc. on 2025-05-13.